Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Effect of baseline CD4 cell counts on the clinical significance of short-term immunologic response to antiretroviral therapy in individuals with virologic suppression.

Moore DM, Harris R, Lima V, Hogg B, May M, Yip B, Justice A, Mocroft A, Reiss P, Lampe F, Chêne G, Costagliola D, Elzi L, Mugavero MJ, Monforte AD, Sabin C, Podzamczer D, Fätkenheuer G, Staszewski S, Gill J, Sterne JA; Antiretroviral Therapy Cohort Collaboration.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):357-63. doi: 10.1097/QAI.0b013e3181b62933.

2.

CD4 cell responses to combination antiretroviral therapy in patients starting therapy at high CD4 cell counts.

Wright ST, Carr A, Woolley I, Giles M, Hoy J, Cooper DA, Law MG; Australian HIV Observational Database.

J Acquir Immune Defic Syndr. 2011 Sep 1;58(1):72-9. doi: 10.1097/QAI.0b013e318225ba62.

3.

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements.

antiretroviral therapy cohort collaboration (ART-CC), Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte AD, Force L, Gill J, Harris R, Hogg RS, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne JA, Costagliola D.

AIDS. 2009 Oct 23;23(16):2199-208. doi: 10.1097/QAD.0b013e3283305a00.

4.

CD4+ response and subsequent risk of death among patients on antiretroviral therapy in Lusaka, Zambia.

Chi BH, Giganti M, Mulenga PL, Limbada M, Reid SE, Mutale W, Stringer JS.

J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):125-31. doi: 10.1097/QAI.0b013e3181ab6d8b.

5.
6.

The effect of tuberculosis treatment on virologic and immunologic response to combination antiretroviral therapy among South African children.

Soeters HM, Sawry S, Moultrie H, Rie AV.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):136-44. doi: 10.1097/QAI.0000000000000284.

7.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.

PMID:
10605973
8.

Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study.

Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J, Anderson J, Gompels M, Dunn D, Johnson MA, Phillips AN, Pillay D, Leen C, Easterbrook P, Gazzard B, Fisher M, Sabin CA.

HIV Med. 2011 Nov;12(10):583-93. doi: 10.1111/j.1468-1293.2011.00929.x. Epub 2011 May 16.

9.

CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.

Moore DM, Awor A, Downing R, Kaplan J, Montaner JS, Hancock J, Were W, Mermin J.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):477-84. doi: 10.1097/QAI.0b013e318186eb18.

PMID:
18989232
10.

HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B; Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group.

JAMA. 2001 Nov 28;286(20):2560-7.

PMID:
11722270
11.

Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, Cameron PU, Petoumenos K, Lewin SR.

PLoS One. 2011;6(6):e20713. doi: 10.1371/journal.pone.0020713. Epub 2011 Jun 2.

12.

Effect of baseline CD4 cell count at linkage to HIV care and at initiation of antiretroviral therapy on mortality in HIV-positive adult patients in Rwanda: a nationwide cohort study.

Nsanzimana S, Remera E, Kanters S, Forrest JI, Ford N, Condo J, Binagwaho A, Bucher H, Thorlund K, Vitoria M, Mills EJ.

Lancet HIV. 2015 Sep;2(9):e376-84. doi: 10.1016/S2352-3018(15)00112-5. Epub 2015 Aug 4. Erratum in: Lancet HIV. 2015 Sep;2(9):e364.

PMID:
26423551
13.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
14.

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Clin Infect Dis. 2014 May;58(9):1312-21. doi: 10.1093/cid/ciu038. Epub 2014 Jan 22.

PMID:
24457342
15.

Predictors of success with highly active antiretroviral therapy in an antiretroviral-naive urban population.

Zaragoza-Macias E, Cosco D, Nguyen ML, Del Rio C, Lennox J.

AIDS Res Hum Retroviruses. 2010 Feb;26(2):133-8. doi: 10.1089/aid.2009.0001.

16.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration.

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

17.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
18.

Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD).

Egger S, Petoumenos K, Kamarulzaman A, Hoy J, Sungkanuparph S, Chuah J, Falster K, Zhou J, Law MG; Asia Pacific HIV Observational Database (APHOD).

J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):513-20.

19.

Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.

Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS.

AIDS. 2006 Feb 14;20(3):371-7.

PMID:
16439870
20.

Discontinuation of antiretroviral therapy in patients with chronic HIV infection: clinical, virologic, and immunologic consequences.

Mata RC, Viciana P, de Alarcón A, López-Cortés LF, Gómez-Vera J, Trastoy M, Cisneros JM.

AIDS Patient Care STDS. 2005 Sep;19(9):550-62.

PMID:
16164382

Supplemental Content

Support Center